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•Atrial fibrillation (AF) - a common supraventricular arrhythmia 
characterized by uncoordinated atrial electrical activity and 
incomplete atrioventricular block with a high risk of 
thromboembolic complications and the development of heart failure 
 
•The frequency of AF increases with age 
 
• 1/3 of all hospital admissions of cardiac rhythm disturbances is 
patients with AF  
 
•Thromboembolic complications and heart failure lead to disability 
and double mortality in patients  
Defenition, frequency, the clinical 
significance 
Types of AF 
 (The recommendations were developed in collaboration with the 
European Heart Rhythm Association (EHRA) and approved by the 
European Association of Cardiothoracic Surgery (EACTS)) 
First diagnosed any first episode of AF, regardless of the duration and severity of 
symptoms 
Paroxysmal sinus rhythm restored alone, usually within 48 hours up to 7 days 
Persistent duration of AF episodes more than 7 days, it is necessary to restore 
the rhythm by medication or electrical cardioversion 
Long-term persistent 
 
AF duration ≥1 year and rhythm control strategy was selected 
Permanent  diagnosed in cases when the patient and physician consider it 
possible to preserve the arrhythmia 
Risk factors for AF  
(The recommendations were developed in collaboration with the 
Heart Rhythm Association (EHRA) and approved by the European 
Association of Cardiothoracic Surgery (EACTS)) 
• Age over 65 years 
• Hypertension 
• Coronary heart disease (CHD) 
•Structural heart disease (valvular dysfunction, hypertrophic 
cardiomyopathy, systolic / diastolic cardiac dysfunction, heart 
failure) 
•Thyroid dysfunction 
•Obesity 
•Diabetes mellitus 
•Chronic obstructive pulmonary disease (COPD) 
•Sleep apnea 
•Chronic kidney disease 
Mechanisms of atrial fibrillation 
(RECOMMENDATIONS of European society of  
Cardiology (ESC) on the management of  
atrial fibrillation (2010)) 
Two hypotheses of atrial 
fibrillation 
• Myocardial remodeling with the development of electrical 
heterogenety and the formation of multiple foci of  
Re-Entre 
 
• Focal trigger activity of myocardial cells in the mouth of the 
pulmonary veins 
Atrial fibrillation on ECG 
The intervals between QRS complexes are different. Heart rate can 
changes from 40-50 to 150 beats/min. P waves are absent. Flickering 
wave (wave F) can be seen in some leads, more frequently in V1. 
Irregular contractions of the ventricles. 
Triggers of atrial fibrillation 
A - Schematic representation of the left and right atrias, rear view. It can be seen  
muscle fibers into the PV. Four main autonomous ganglion plexus LA and their 
axons (upper left, lower left, front right, bottom right) showed by yellow color. 
Coronary sinus, and a bunch of Vienna Marshall, who comes from the coronary 
sinus to the area between the left superior PV and LA eyelet showed by blue color.  
B - Large and small waves re-Entre playing a role in the initiation and 
maintenance of AF.  C - The most frequent location of the triggers of AF in LV 
(shown in red) and the trigger is PV (shown in green) D - The combination of 
anatomical and arrhythmic mechanisms of AF. 
Rationale for catheter ablation of AF 
The objectives are the prevention of AF ablation by applying radiofrequency energy 
and either remove the trigger that initiates AF or change arrhythmogenic substrate. 
The most frequently used today ablation strategy, which includes electrical isolation of 
pulmonary veins by creating openings around the peripheral damage of the right and 
left pulmonary veins probably affects both the trigger and the substrate AF. 
A - circular impact around the 
right and left PV 
B - line exposure ("line on the 
roof“,  line "mitral isthmus") 
C - eight-like shaped line 
ablation  
D - areas with complex 
fractionated endogrammams. 
Radiofrequency ablation 
•Nowadays the radiofreguency ablation is the most promising and 
rapidly growing method of treatment of AF. 
By the evidence of leading international arrythmic centers the efficiency 
reaches 60-95%. 
•Complications (deep vein thrombosis or clot propagation by 
subcutaneous veins) are extremely rare (1-2%). 
Class I. 
1) Patients with atrial tachycardia resistant to the action of drugs, as well as intolerance of drugs by the 
patient or his unwillingness to continue long-term antiarrhythmic therapy. 
2) Patients with atrial tachycardia, when the latter is combined with the "focus" of paroxysmal (continuously-
recurrent) atrial fibrillation from the clutches of the pulmonary veins, the superior vena cava and the mouth 
of the coronary sinus, the left and right atria, resistant to the action of drugs, as well as intolerance of drugs 
the patient or his unwillingness to continue long-term antiarrhythmic therapy. 
3) Patients with atrial flutter resistant to the action of drugs or RFA of AF, as well as intolerance of drugs by 
the patient or his unwillingness to continue long-term antiarrhythmic therapy. 
Class II. 
1) atrial fibrillation / atrial tachycardia associated with paroxysmal and persistent atrial fibrillation, 
tachycardia unless resistant to drugs, as well as intolerance of drugs by the patient or his unwillingness to 
continue long-term antiarrhythmic therapy. 
2) Patients with paroxysmal and persistent  atrial fibrillation, provided that starting or supporting factors 
arrhythmias are clearly localized (pulmonary veins, atria) of its occurrence, if tachycardia resistant to 
drugs, as well as intolerance of drugs by the patient or his unwillingness to continue long-term drug 
therapy. 
Class III. 
1) Patients with atrial fibrillation are amenable to drug therapy if the patient tolerates treatment and prefers to 
conduct its ablation. 
2) Patients with chaotic atrial tachycardia. 
 
 
 
 
 
Indications for  AF catheter ablation 
Contraindications for radiofrequency catheter 
ablation of AF 
Absolute Relative 
inability to use anticoagulant therapy decompensation of chronic heart failure 
atriomegaly (LA sagittal dimension larger than 50 mm 
or a volume more than 200 ml) 
circulatory failure III-IV functional classes 
life-threatening cardiac or non-cardiac status severe renal insufficiency 
inability to puncture the femoral vein exacerbation of peptic ulcer 
lack of consent of the patient and / or his legal 
representatives of the procedure 
allergy to drugs (local anesthetics, narcotic drugs); 
inflammatory diseases of the heart and surrounding 
structures; 
lack of access to large vessels and / or violation of 
their permeability; 
exacerbation of chronic diseases; 
impossibility of receiving antiarrhythmic drugs. 
Technique  radiofrequency catheter 
ablation (RFA) 
•The operation is performed under local anesthesia 
•Femoral and subclavian vein are punctured 
•Catheter-electrode introduced through punctate via the introducer 
under X-ray control into the heart cavity 
•The first stage is the heart electrophysiological investigation (EFI) 
performing with the induction of tachyarrhythmias and localization of 
arrhythmogenic substrate is influenced by the energy of radio 
frequency current  
•After 20 minutes, a repeated EFI to assess the effectiveness of the 
impact 
•Patients are advised to strict bed rest to 24 hours. 
•Rehabilitation after RFA for several months, during which can be 
assigned the antiarrhythmic drugs 
Result of Radiofrequency Catheter Ablation 
(RFA) 
After ablation: chaotic impulses 
that trigger arrhythmia can not 
fall into the cavity of the atrium 
Complications after AF catheter ablation 
•Embolism, transient ischemic attacks, strokes 
• Stenosis / occlusion of the pulmonary vein 
• Appearance of atrio-esophageal fistula 
•Cardiac tamponade 
•Phrenic nerve damage (primarily the right) 
•Damage to the esophagus 
•Arterio-venous fistula 
•Aneurysm formation 
•Radiation injury 
•Damage to the mitral valve 
•Acute coronary artery disease 
•Air embolism 
•Hematoma at the puncture site 
•Mortality 
Mechanisms of AF recurrence after 
catheter ablation 
 The highest risk of recurrence of AF during the first 6 - 12 months after 
ablation, there is the risk of ‘new’ late repeated appearance of AF 
  
•The basic mechanism - electrical reconnection of the pulmonary veins 
•The presence of arrhythmogenic foci, which were not identified and isolated during 
the first ablation 
•Postablation result of changes autonomic innervation of the heart and the 
pulmonary veins 
•Result of fisiological aging, heart failure (HF), inflammation 
•associated diseases: diabetes mellitus, sleep apnea, hypertension, 
hypercholesterolemia 
 
 The hybrid approach (surgery combined with medication) can significantly 
improve the quality of life by reducing the number of attacks and symptoms of 
arrhythmia 
Management of patients with atrial fibrillation 1  
(Recommendations of the American College of Cardiology, the American 
Heart Association and the European Society of Cardiology for the 
management of patients with atrial fibrillation (ACC / AHA / ESC 2006) 
Basic methods of therapy: 
 
1. Restoration of sinus rhythm 
 
 1.1. Drug cardioversion 
 
 1.2 Electro-Cardioversion Defibrillation 
 
 1.3 Surgical methods 
 
2. Anticoagulation 
 
3. preventive treatment 
 
4. Treatment of the underlying disease 
Management of patients with atrial fibrillation 2 
1.1.drug cardioversion 
Drug Daily dose Features of administration  
Chinidin sulfate 300-600 mg once Drugs of IA, IC classes: using in patients without 
myocardial  structural lesions. 
Flecainide or propafenone are not used for a long time, but 
only for  attack releaving. 
Novokainamid 1000-4000 mg 
Flecainide 50-400 mg 
Propafenone 450-900 mg 
Dofetilide 500-1000 mg  
Amiodarone 100-400 mg 
 
In the presence of cardiac disease. In the case of left 
ventricular dysfunction, MI 
and CHF. 
Sotalol 480 mg  (up to 640 mg) 
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1.2 Electro-cardioversion defibrillation (ECD) – transthoracic  
 impact of sufficient force to cause depolarization of the entire myocardium,  
the sinoatrial node and then resumes control of the heart rhythm. 
 
● Cardioversion - the impact of direct current  synchronized with  
the QRS complex 
 
● Defibrillation - the impact of direct current without complex 
 synchronization QRS. 
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1.3. surgical 
 
• AV-node radiofrequency catheter ablation (AV-modulation of the slow destruction  
of the α-ways, destruction AV- node with pacemaker implantation - preferred  
biventricular pacing) 
 
• endovascular catheter ablation (in the left atrium: focal ablation,  
ablation of ganglionic plexuses, the isolation of the pulmonary veins;  
isthmus ablation of the right atrium) 
 
•Implantation of automatic atrial defibrillator 
 
•Surgical isolation of the left atrial surgery - MAZE (I-III) ("Labyrinth") 
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2. Anticoagulation therapy 
 
Anticoagulants (at low risk of bleeding) 
•Warfarin inside 5mg / day initial dose titrated to a target INR of 2.0-
3.0 (unless contraindicated), or 
 
•Dabigatran 110 mg 2 times a day, or rivaroxaban 10,15, 20 mg / day 
(subject to availability bruising patient) in 1 reception. 
 
Antiplatelet agents 
 
•Acetylsalicylic acid 75 mg / day after the meal 
 
•Clopidogrel 75 mg per day. 
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Groups of drugs Member of drug groups Features of administration 
Calcium antagonists 1. Verapamil inside of 40-80 
mg 3-4 times/ day. 
2. Diltiazem inside at 60-180 
mg 2 times / day. 
Beta-blockers 1. Sotalol 160 mg 2 p / day. 
2.5-10 mg bisoprolol inside 1 
times / day. 
2. Betaxolol inside 50 mg 2 
times/ day. 
3. Metoprolol inside of 50-100 
mg 2 times / day. 
4. Propranolol inside the 80-
240 mg / day. 
Combination with 
amiodarone or class 1C 
drugs (flecainide, 
propafenone) 
Statins  1. Atorvastatin 10 mg/ day. 
2. Lovastatin, 20 mg / day. 
3.Simvastatin 20 mg / day. 
4. Fluvastatin 20 mg / day. 
3. Preventive treatment: 
Our patient 
• Woman 
• 72 year old 
• retired 
• A townswoman 
• Date of admission: October 2014 
 
Complaints 
• Seizures disruptions of the heart and heart palpitations (heart rate over 
130 beats / min) without warning and a clear link to the provoking 
factor, accompanied by discomfort in the heart, weakness, lasting 
from 15 minutes to 2-3 hours stopped by taking 300 mg Propanorm . 
• Headache in the occiput, inner discomfort that arise for no apparent 
reason, often with an increase in blood pressure to 150-160 / 90 mm 
Hg, which is relieved by drugs (losartan or amlodipine) for 1.5-2 
hours. 
• Shortness of breath, heart palpitations, fatigue, arising from the 
normal exertion. 
• Recurrent pain in the cervical spine, interscapulum. 
• Recurrent pain in the right knee that occur after exercise. 
Medical history 1 
 Since 2000, blood pressure unstability with the rise to 150-160/90 mmHg 
(maximum 200/100 mm Hg), familiar to the patient - 140/80 mm Hg 
Repeatedly she was treated in the cardiology department of the Central 
Clinical Hospital № 5 and at the hospital in the community about arterial 
hypertension and sinus bradycardia. 
 Since 2004, the attacks of palpitations (heart rate over 130 beats / min), up to 
2 times a month, arise spontaneously, without warning and a clear link to the 
provoking factor, often at night, accompanied by general weakness, headache, 
discomfort in the heart. Most of the attacks proceeded with loss of 
consciousness. Sinus rhythm was restored spontaneously within 10 minutes to 
1 hour. During the next 2 years the duration of attacks increased up to 2-2.5 
hours. 
 Since 2006, the paroxysms of self is not docked. The patient was admited in 
the hospital, with diagnosed persistent AF. 150 mg propanorm was appointed 
to restore sinus rhythm . On the background of the drug short paroxysms 
began to cut for 1 hour . 
  Since 2012 she was increased Propanorm dose herself up to 300 mg  
  Since 2013 the number of attacks increased up to 2-3 times a day. 
 
Medical history 2 
 In July 2013 there were planned treatment in CCH №5. Losartan, Warfarin, 
Nebivolol, Propanorm were taken situationally after discharge. Warfarin  was 
canceled because of gross hematuria  
 June 2013 - February 2014 the frequency of attacks was maintained (2-3 times 
a day), every second attack was accompanied with loss of consciousness. 
Nightly episodes were dominated, because of what the sleep was disturbed. 
 In February 2014 the catheter ablation of pulmonary veins (removal of AF 
and slow path) was conducted at the N.M. Amosov Institute of Cardiovascular 
Surgery. AF attacks were  stored after the operation on the background of 
bradycardia during the rest (50 beats / min). The incidence of attack was 1-2 
times a week and was not accompanied by syncope. The patient receives 
Losartan 25 mg, Carvedilol 12.5 mg Amlodipine 2.5mg systematically. 
 From 1 to 9 October 2014 there were 7 attacks (almost daily), stoped by  
Propanorm 300 mg during 2-3 hours. The increase of episodes the patient 
connects with the reception of the gelatin mixture (which was taken as a folk 
remedy for treatment of osteoarthritis). Repealing gelatin patient noted a 
decrease in paroxysms (up to 3 times a week). 
 Current hospitalization on CCH №5 planned for control after catheter 
ablation. 
 
Life history 
1.Electrician by profession. From 1962 to 1999 she worked in 
office manager, professional stress was noted. 
2.Injuries: bruised right knee in childhood. 
Since 1986, osteochondrosis of the cervical-thoracic spine. 
Secondary gonarthrosis. 
1973 appendectomy. 
February 2012 there was conducted puncture of the right kidney cyst. 
Tuberculosis, diabetes, sexually transmitted diseases, viral hepatitis, rheumatism, 
mental illness history denies. 
Family history is not burdened. 
Allergic history (intolerance to warfarin and  sinkumar - gross hematuria). 
No bad habits. 
 
Lifestyle of the patient 
• The patient does not smoke, does not drink alcohol 
• Controls body weight 
• Nutrition includes eating more fruits and vegetables, as 
well as products low in animal fats in the diet and the 
prevalence of vegetable fats. In cooked food adheres 
most gentle ways (decoction, stewing and steaming) 
• Reduced consumption of salt (about 1 g daily). 
• Of exercise 5 times a week (gymnastics, charge), 
swimming 2 times a week. 
 
Objective status 
The general condition is satisfactory, consciousness is clear, emotionally stable, optimistic 
mood. 
Normosthenic physique, height 165 cm, weight 56 kg, BMI = 20.7 kg / cm2 
Skin, visible mucous membranes pale pink and clean. 
Peripheral lymph nodes were not enlarged. 
Lobe of the thyroid is not palpable, the isthmus is palpated in the form of a uniform cross-
strand smooth, 1 cm wide 
Musculoskeletal system without singularities, pain in the neck palpation and poorly 
marked tenderness of the right knee with patellar displacement in the projection of joint 
space 
Respiratory System: Pulmonary percussion sound auscultation - vesicular breathing, no 
additional noise. 
CCC: the left boundary of the relative dullness of 5 m / d in the mildclavicular line, 
rhythmic activity of the heart, heart sounds are muffled, accent II tone of the aorta. Heart 
rate = heart rate = 50 beats / min. Blood pressure of 140/90 mm Hg. Art. against the 
background of antihypertensive therapy. 
Stomach of normal size, palpation soft, painless. Liver 2 cm protrudes from under the 
costal margin, painless. 
No peripheral edema. 
                 PLAN OF SURVEY IN THE HOSPITAL  
 1. Complete blood count 
 2. Urinalysis 
 3.Biochemical  blood analysis (cholesterol, bilirubin, ALT, AST, glucose, 
creatinine, urea) 
4. Chest X-ray 
5.ECG 
6.Holter ECG 
7. Ultrasound of the heart with the doppler analysis 
8. Ultrasound of abdomen 
Additional recommended           
• Blood lipid profile (LDL, VLDL, HDL, triglycerides) 
• Ultrasound of Thyroid Gland 
•  TSH, T3, T4 
• Neurologist consultation 
• X-ray of the cervical-thoracic spine and right knee 
 
 
 
Complete blood count (21/10/2014)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All values in the normal range 
 
 
 
 
 
 
• All values in the normal range 
NORMAL RESULT INDEX 
120 -140 g/l  140 g/l hemoglobin 
3.9 -4.7 4.62 erythrocytes 
0.85-1.15 0.9 CPU 
36-42% 41.3% hematocrit 
160-320g/l 261g/l  thrombocytes 
4.0-9.0g/l 5.6g/l leukocytes 
1-6% 2% stab 
47-72% 62.9 segmented 
 
0.5-5.0% 3% eosinophils 
0-1.0% 1.2% basophils 
19-37% 24% lymphocytes 
3-11% 6.9% monocytes 
 
2-15mm/h 7mm/h ESR 
Urinalysis (10/21/2014) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All values in the normal range 
NORMAL RANGE  RESULT INDEX 
70.0 AMOUNT (ml) 
Light Yellow Yellow  Color 
transparent 
 
transparent TRANSPARENCY 
 
1.001-1040 1.010 OTNOS.PLOTNOST 
5.0-6.0 6.0 REACTION (pH) 
 to 0.033g/l not found PROTEIN (g / l) 
- Not found  Glucose (mmol / l) 
 
6-8 1-2 leukocytes 
 
Not found  TRANSITIONAL EPITHELIUM 
 
Not found  BACTERIA 
Biochemical analysis of blood (21/10/2014 
 
 
  normal  range  Result  Index  
<5.2MMOL/L 5.58 total cholesterol 
1.7-21.0 MMOL/L 24.15 total bilirubin 
 
<3.4 MMOL/L 7.5 direct 
<19MMOL/L 16.65 indirect 
<31M/L 16 ALT  
TO 0.5 MMOL/L 0.34 AST  
53-97MMOL/L 91.6 creatinine 
4.2-6.1MMOL/L 5.51 glucose 
4.2-8.3MMOL/L 5.2 urea 
Chest X-ray (10/21/2014) 
Focal and infiltrative changes in the lungs were 
not identified. The roots of the structural, not 
increased. 
Right pleuro-diaphragmatic sinus obliterated. 
 Diaphragm  clearly delineated. 
 
Heart enlarged to the left. Aortic arch with 
sclerotic changes. Determined by the extension of 
the upper mediastinum. 
 
 
ECG (10/20/2014) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sinus rhythm, right. Left ventricular hypertrophy, heart rate 53 beats / min. 
Comparison the results of daily ECG monitoring 
before and after RFA 
 
After RFA 
(21/10/14) 
Before RFA (10/01/14) Index  
Day 53 bpm  
Night 48 bpm  
Day  76 bpm 
Night 79 bpm  
The average heart rate during the 
observation 
82 beats / min 
 
105 beats / min 
 
Maximum heart rate 
40 beats / min 45 beats / min Minimum heart rate 
total 6 total 2 Single supraventricular extrasystoles 
 
only 2 (1 day, 1 
night) 
 
total 13 Single polymorphic ventricular 
extrasystoles 
not found 
 
Long with a heart rate of 116 to 
208 beats / min, 
Short with a heart rate of 116 to 
151 beats / min. (58 hours) 
AF paroxysm 
not found In a depression to 2mm 0.08 
seconds in the period before the 
increase in heart rate max (208 
beats / min) 
ischemic changes 
ST-T 
AF Paroxysm Holter ECG monitoring before RFA 1 
(10.01.14) 
 
Ultrasound of the heart with Doppler analysis (21/10/14) 
• Aortic regurgitation, grade 2. 
• Mitral valve prolapse, grade 3 
• The cavities of the heart are not enlarged. 
• Signs of increased pressure in the pulmonary artery. 
• Indices of myocardial contractility and pump function 
of the left ventricle are saved. 
• Mitral regurgitation, 1 degree. 
• Tricuspid regurgitation,1 degree. 
• Abnormal left ventricular chord 
Comparison the results of echocardiography of the heart, with the Doppler 
analysis before and after RFA 
 After RFA (21/10/14) Before RFA (01/11/14) Index   
diameter 31 mm, wall 
echodensity enhanced 
thickened wall 
diameter 34 mm, wall 
echodensity enhanced 
thickened wall 
 
aorta 
Opening the valves 21 mm 
sash thickened. Regurgitation 
of II degree 
Opening the valves 16.0 mm, 
sash thickened. Regurgitation 
has traces 
Aortic Valve 
 
Not extended, anteroposterior 
dimension of 32.8 mm 
 
extended, anteroposterior 
dimension 37.6 mm 
 
Left atrium 
EF ejection fraction of 65% 
Fractional shortening FS 36% 
EF Ejection fraction 65% 
Fractional shortening FS 36% 
Left ventricle 
not extended, the diameter of 
36.8 mm 
 
not extended, the diameter of 
35.6 mm 
 
Right atrium 
Not expanded, diameter 22 
mm, thickness of the front wall 
5 mm, thickened 
 
Not expanded, diameter 22.1 
mm, thickness of the front wall 
of 5.6 mm, thickened 
 
The right ventricle 
 
Lotsiruetsja. The flaps are not 
changed. Regurgitation 
physiological I degree. 
Lotsiruetsja. The flaps are not 
changed. I have a degree of 
regurgitation. 
The pulmonary valve 
 
Ultrasound of the abdomen and kidneys 
(10/21/14) 
 
 hepatomegaly 
 Diffuse parenchymal changes in the liver and 
pancreas 
 Cyst of the right kidney, measuring 46.7 mm. 
Basic clinical syndromes 
 
 Atherosclerosis (sclerotic changes of aortic and 
mitral valves, mild atherosclerotic aortic stenosis). 
 Arterial hypertension 
 Arrhythmias (persistent AF) 
 Heart failure 
 Hepatomegaly 
 Articular syndrome (osteochondrosis of the 
cervical-thoracic spine, right secondary 
gonarthrosis) 
 Right kidney liquid formation  
Clinical diagnosis (According 
to the classification) 
Classification of CHD 
 (On the recommendations of the European Society of Cardiology ESC, 2013) 
1. sudden coronary death 
1.1. Clinical sudden coronary death with successful resuscitation 
1.2. Sudden coronary death (fatal case) 
2. Angina 
2.1.1. Stable angina (indicating the functional classes (FC). 
2.1.2. Stable angina with angiographically intact vessels (coronary syndrome X). 
2.2. Vazospastichna angina (angiospastic, spontaneous, variant, Printsmetalla). 
2.3 Mixed angina 
2.4 Unstable angina (up to 28 days) 
2.4.1. Angina, which appeared for the first time to 28 days (angina that occurred for the first time, with transient ECG changes - rest). 
2.4.2. Progressive angina (angina at rest or the appearance of night attacks in a patient with angina pectoris, angina change, progressive decrease in exercise 
tolerance, transient ECG changes - rest). 
2.3.3. Early post-infarction angina (from 3 to 28 days). 
3. Acute myocardial infarction 
3.1. Acute myocardial infarction with the presence of wave Q (transmural, macrofocal) 
3.2. Acute myocardial infarction without tooth Q (melkoochagovy). 
3.3. Acute subendocardial myocardial infarction. 
3.3 Acute subendocardial myocardial infarction 
3.4. Acute myocardial infarction (unspecified) 
3.5. Recurrent myocardial infarction (from 3 to 28 days). 
3.6. Recurrent myocardial infarction (after 28 days 
3.7. Acute coronary insufficiency. The diagnosis of intermediate - elevation or depression of segment ST, which displays acute ischemia to develop signs of 
myocardial necrosis or sudden coronary death 
4. Cardiosclerosis 
4.1. focal kardiosklerosis 
4.1.1. Myocardial infarction with an indication of the form and stage 
heart failure, arrhythmias and nature 
conductivity, the number-myocardial, their localization and time of occurrence). 
Chronic cardiac aneurysm 
4.1.2. Focal cardio, without indicating myocardial infarction. 
4.2. Diffuse cardioscrerosis  (with an indication of the stage of heart failure, arrhythmias and conduction) 
5. painless form of CHD. 
Classification of hypertension according to the level of blood pressure 
(Recommendations by the Ukrainian Association of Cardiologists Prevention and 
treatment of hypertension, 2008) 
 Diastole   Systole  The degree of hypertension 
90-99 
 
140-159 
 
 
Hypertension 1st severity 
(mild) 
 
100-109 
 
160-179 
 
Hypertension 2nd severity 
(moderate) 
>= 180  
 
>= 180  
 
Hypertension 3rd severity 
(severe) 
 
Classification of hypertension stages   (Recommendations 
of the Association of Cardiologists of Ukraine 2008) 
The degree of target organ damag 
 
stage 
Objective changes in the target organs are absent                         I 
There is objective evidence of target organ damage without symptoms with their 
hand or dysfunction: 
  Left ventricular hypertrophy (on ECG, ultrasound, Ro); 
generalized narrowing of retinal arteries; 
Microalbuminuria and / or a small increase in serum creatinine (y 
m. - 115 - 133 mmol / L at x. - 107 - 124 mmol / l); 
carotid artery disease - a thickening of the intima-media> 0.9 mm or the presence of 
atherosclerotic plaques. 
 
 
 
II 
 
 
There is objective evidence of target organ damage with symptoms from their 
side and impaired 
  heart - myocardial infarction, heart failure II A - III stage; 
  brain - stroke, transient ischemic attack, acute hypertensive 
encephalopathy, vascular dementia; 
  fundus - hemorrhage and retinal exudates with papilledema 
the optic nerve or without; 
  Kidney - concentration of plasma creatinine in males> 133 umol / L, y 
Women> 124; 
  vessels - dissecting aortic aneurysm; peripheral arterial occlusion 
 
III 
 
Risk stratification of hypertension 
 (Recommendations Ukrainian Heart Association, 2008) 
 
Hypertension 
3rd degree> 
180/110 
 
Hypertension 
2nd degree 
160-179 / 100-
109 
Hypertension 
1st degree 
140-159 / 90-99 
high 
normal 130-139 / 
85-89 
risk Factors 
 HIGH RISK MODERATE 
RISK  
LOW RISK  ------ NO  
VERY HIGH 
RISK  
MODERATE 
RISK  
MODERATE 
RISK  
LOW RISK 1-2 RISK 
FACTOR  
 VERY HIGH 
RISK  
 
HIGH RISK  
 
HIGH RISK  
 
HIGH RISK  
 
 MORE THAN 3 
RISK FACTOR  
VERY HIGH 
RISK  
 
VERY HIGH 
RISK  
 
VERY HIGH 
RISK  
 
VERY HIGH 
RISK  
 
accompanying 
clinical 
States 
 
Classification of atrial fibrillation 
(HRS / EHRA / ECAS Expert Consensus Statement on Catheter and Surgical 
Ablation of Atrial Fibrillation, 2012; Recommendations of Ukrainian Heart 
Association, 2011) 
 By the flow  
•     Paroxysmal (lasting less than 7 days.) 
•     Persistent (lasting more than 7 days.) 
•     Permanent (long-existing AF, cardioversion is ineffective or not 
done) 
 
By AV conducting status 
•     The correct form - regular 
•     Irregular shape - irregular 
 
According to the frequency of ventricular rhythm: 
•    Tachy  variant (HR over 90 beats / min) 
•     Normo variant (HR 60-90 beats / min) 
•     Brady variant (HR below 60 beats / min) 
CHA2DS2-VASc rating Scale risk of thromboembolic complications in 
patients with Fibrillation / atrial flutter  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Score 3. The expected frequency of strokes per year 3.2% 
Points RISK FACTOR  
2 Stroke, transient ischemic attack, or 
thromboembolism 
2 Age ≥ 75 years 
1 arterial hypertension 
 
1 diabetes mellitus 
1 Congestive heart failure / 
LV dysfunction (ejection fraction ≤ 40%) 
1 Cardiovascular disease (history of myocardial infarction, 
peripheral atherosclerosis, 
atherosclerotic plaques in the aorta) 
1 AGE 65-74 YEARS  
1 Woman sex 
 
Total points 3. The expected frequency of strokes per year 3.2% 
  
 
 
SCALE HAS-BLED: risk factors for bleeding 
 (ESC Guidelines for the management of atrial fibrillation, 2011) 
 
 
  
 POINTS RISK FACTOR 
 
 Arterial hypertention (SBP > 160 мм.рт.ст.) 
 
1 Abnormal liver function, severe cartilage. disease or increased 
bilirubin ≥2 times the upper limit of normal in conjunction with 
povysheniem≥ AST / ALT ≥ 3 times 
1 Impaired renal function: creatinine ≥ 200, dialysis and transplantation 
1 insult 
1 Bleeding history or predisposition 
1 Labile INR (unstable or high in the therapeutic range 
less than 60% of the time) 
1 Age over 65 years 
1 alcohol abuse 
1 Acceptance of others. Drugs that increase the risk of bleeding 
(NSAIDs, antiplatelet agents, and before.) 
Clinical stage of chronic  Heart failure (CHF) 
 (By Strazhesko ND, VH Vasilenko, 1935; Ukrainian recommendations of Heart 
Association for diagnosis, treatment and prevention of heart failure, 2013) 
 
clinical Manifestations 
 
stage 
Starting hidden, appear only on exertion as breathlessness, 
tachycardia, excessive fatigue, expressed sharper and longer than in the healthy 
human. Hemodynamics and organ function is not impaired; earning capacity 
lowered. 
I 
 
Signs of hemodynamic instability. Metabolic and 
the function of other organs 
II 
 
Insufficiency of the right or left of the heart. Stagnation and disruption 
the function of other organs are mild and usually manifest by the end of the 
working day 
or after exercise (disappear after a night of rest) 
II A 
 
Failure of right and left heart chambers. Stagnation of blood expressed 
stronger and occur at rest (do not disappear after a night's rest, may be slightly 
decrease) 
II B 
 
Certainly, dystrophic CH with severe hemodynamic resistant 
Metabolism and functions of all the organs, the development of irreversible 
changes in the structure of organs and tissues, and disability. 
III 
 
  Functional class of heart failure  
              (According to the criteria of the New York Heart Association - NYHA) 
clinical characteristics RISK 
FACTOR  
Patients with cardiac disease whose ordinary physical activity does not cause 
shortness of breath, fatigue, or palpitations  I 
 
 
Patients with heart disease and moderate limitation of physical activity. Under  
normal physical activities observed Dyspnea, fatigue, and palpitations 
 
II 
 
Patients with cardiac disease and marked limitation of physical activity. At rest, 
there are no complaints, but even minor physical exertion dyspnea, fatigue, 
palpitations 
 
III 
Patients with cardiac disease in which any physical activity level is above the 
subjective symptoms. These arise dormant 
IV 
 
Variants of left ventricular dysfunction  
 (Ukrainian Heart Association Guidelines for diagnosis, treatment and 
prevention of CHF, 2013). 
Variant I Left ventricular systolic dysfunction: 
ejection fraction less than 40%  
 
 
Variant II. Preserved systolic function: ejection 
fraction greater than 40% 
DIAGNOSIS 
 
 
 
On admission:  
Arterial hypertention II stage, 3 degree, high 
risk. CHD. Atrial fibrilation  paroxysmal 
form. Tachysystole. Condition after 
pulmonary vein isolation  (24.02.14). CHF I 
st.  
Clinical: 
CHD. Aorta atherosclerosis, mild 
atherosclerotic aortic stenosis, 
atherosclerotic cardiosclerosis. Sinus 
bradycardia. Persistent atrial fibrillation, 
tachysystolic form. Condition after 
pulmonary veins isolation (February 
2014). HAS-BLED score 3 points, 
CHA2DS2-VAS score 3 points. 
Arterial hypertension stage II, mild 
degree, moderate added risk. 
Chronic heart failure stage I, II FC with 
preserved LV systolic function. 
Comorbid conditions: 
Osteochondrosis of the cervical-thoracic 
spine. Right secondary gonarthrosis. 
Right kidney liquid formation (cyst), size 
46.7 mm. 
 
Treatment in hospital 
 Acetylsalicylic acid 75 mg 
 Carvedilol 12.5 mg 2 times / day. 
 Valsartan 80 mg 2 times / day. 
 Trimetazidine 1t. 2 times / day. 
 Kardioarginin 5 ml / Cap. 2 times / day 
 Meldonium 100 mg / ml in / pp. (Cardiac) 
 Nikomeks (Emoxypine) –i/v 75 mg 2 times / day. 
(Drugs affecting the nervous system) 
 Thiotriazoline 2.5% i/v. № 10 
 
Recommended treatment 
1. Lifestyle modification: 
•                  Change in daily routine (sleep duration of at least 8 hours per 
day; day sleep 1-2 hours). 
•                 Continued adherence to diet and physical activity. 
2.Drug therapy: 
•            Losartan 50 mg / day. 
•            Atorvastatin 10 mg at bedtime 
•            Aspirin 75 mg / day. 
•             Propafenone 150 mg - with paroxysm 
•             Local medication (NPVS- ointments) 
•             Physiotherapy 
Differences in treatment after radiofrequency catheter ablation 
Treatment in hospital                   
 Acetylsalicylic acid 75 mg 
 Carvedilol 12.5 mg 2 p / day. 
 Valsartan 80 mg 2 p / day. 
 Trimetazidine 1t. 2 p / day. 
 Kardioarginin 5 ml / Cap. 2 p / day 
 Meldonium 100 mg / ml in / pp. (Cardiac) 
   Nikomeks-in / in / Cap. 75 mg 2 p / day. 
 Thiotriazoline 2.5% w / p. № 10 
 
The recommended treatment 
 
Losartan 50 mg / day. 
Atorvastatin 10 mg at bedtime 
Aspirin 75 mg / day. 
Propafenone 150 mg at paroxysm 
 
 
 
PROGNOSIS  
 for life, with compliance - satisfactory 
 to recovery: adverse 
With persistent AF catheter ablation success probability is about 
65%, with about 40-50% of patients require re-ablation 
 
In addition to re-establish communication between the isolated 
pulmonary veins with atrial tissue main cause arrhythmias after 
ablation is an iatrogenic atrial tachycardia mechanism re-entry 
 
The most effective results radiofrequency ablation shows early 
development of AF. 
 
PREVENTION 
1.Maintain a healthy lifestyle 
•    diet 
•    perform physical activities 
•    avoiding harmful habits 
•    avoidance of emotional tension 
2. Maintaining body mass indices and cholesterol, and glucose 
in normal 
3. The patient should be evaluated after 3 months. after 
radiofrequency ablation, and then every 6  months. for at least 
2 years 
4. A person suffering from arrhythmia, should take medication 
constantly (to prevent or treat). 
THANK YOU FOR YOUR ATTENTION 
 
